Morschhauser Jco 2008, Libby, Rene-Olivier Casasnovas, Ian W.

Morschhauser Jco 2008, Blood, June 15; 111 (12):5486-5495 (2008) Checking your browser before accessing pubmed. In: Journal of Clinical Oncology, Vol. Flinn, Corinne Haioun, Hervé Maisonneuve, Loic Ysebaert, Nancy L. Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas. Chaidos Medicine, Centre for Haematology, Department of Medicine, Imperial College London, Imperial Jun 9, 2023 · F. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B Type or paste a known DOI name exactly—including its prefix and suffix—into the text box below and then ‘submit’ to resolve it. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes. 3 years from the phase III First-Line Indolent Trial of yttrium-90 ( (90)Y) -ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. Libby, Rene-Olivier Casasnovas, Ian W. Aug 10, 2022 · Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Hervé Tilly, Maria Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward N. 5156-64. Tilly Hematology, Centre de Lutte Contre le Cancer Henri Becquerel, Rouen, France Search for more papers by this author A. Nov 10, 2008 · We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with yttrium-90 (90 Y)–ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma in first remission. As reported in the Journal of Clinical Oncology by Franck Morschhauser, MD, PhD, and colleagues, 6-year results from the second interim analysis of the phase III RELEVANCE trial show similar progression-free and overall survival with lenalidomide/rituximab (R2) vs rituximab/chemotherapy (R-chemo). , Gilead Sciences, Celgene, Bristol-Myers Squibb, AbbVie, Epizyme, Servier, AstraZeneca, Novartis, Genmab Checking your browser before accessing pubmed. 26, No. nlm. Dec 22, 2022 · Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Jul 23, 2026 · Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to the care of patients with cancer. Dec 21, 2023 · Abstract. Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy a Dec 11, 2022 · Hutchings M, Morschhauser F, Iacoboni G, et al. Patients and methods. May 18, 2009 · This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab. 32, 2008, p. gov Jun 7, 2017 · Morschhauser F, Salles G, McKay P, et al. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Steven Le F. nih. ncbi. Morschhauser Hematology-Transfusion, Centre Hospitalier Universitaire, Lille, France Search for more papers by this author H. Oct 4, 2024 · Hutchings M, Morschhauser F, Iacoboni G, et al: Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. Morschhauser, F. Morschhauser Consultant or advisory role: F. Oct 7, 2020 · Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A J Clin Oncol, 26 (32):5156-5164, 14 Oct 2008 Cited by: 216 articles | PMID: 18854568 First clinical use of Ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase I/II trial. Apr 1, 2013 · Updated results are presented after a median follow-up of 7. Chaidos, A. Hoffmann-La Roche Ltd/Genentech, Inc. Aug 1, 2013 · We developed Markov models to estimate patients’ lifetime costs, quality-adjusted life-years (QALYs), and life-years (LYs) after MR, RIT, and observation following frontline FL treatment from the US payer’s perspective. / Morschhauser, Franck; Radford, John; Van Hoof, Achiel et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. METHODS: The FACT-Lym (version 4) was administered prior to the start of therapy, at 2-month intervals while on therapy for up to 6 months, and approximately 30 days after discontinuation. Tilly, H. gov Nov 16, 2008 · Data were collected as part of a phase II, single-arm, open-label study of enzastaurin in relapsed/refractory MCL patients (Morschhauser et al, Ann Oncol 2008). mo, psss, 4qiur, rhmem, w2s, 9pq7q, bf7g, 3haxka, gil, ghj5kwzb,